[A17-14] Baricitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V

Last updated 03.07.2017

Project no.:

Commission awarded on 31.03.2017 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Muscles, bones and joints


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Current document

Project no. Title Status
A17-36 Baricitinib (rheumatoid arthritis) - Addendum to commission A17-14 Commission completed


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.